2673-818x

Frontiers in Virology

Frontiers Media SA

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 330 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact330 DOIs
2

Add abstracts to 43 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact43 DOIs
3

Deposit reference lists for 10 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact10 DOIs

DOIs for this ISSN

Showing the top 5 of 330 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Vaccines and Antivirals: Grand Challenges and Great Opportun… (10.3389/fviro.2021.666548)
Abstract ORCID
83.14 45
2 Renewed global threat by the novel SARS-CoV-2 variants ‘XBB,… (10.3389/fviro.2022.1077155)
Abstract ORCID
65.05 19
3 Prioritizing the Continuing Global Challenges to Emerging an… (10.3389/fviro.2021.701054)
Abstract ORCID
55.70 12
4 Five Challenges in the Field of Viral Diversity and Evolutio… (10.3389/fviro.2021.684949)
Abstract ORCID
53.96 11
5 Cotton blue disease from Africa and its de facto relationshi… (10.3389/fviro.2023.1253174)
Abstract ORCID
52.07 10
6 Can a Torque Teno Virus (TTV) Be a Naked DNA Particle Withou… (10.3389/fviro.2022.821298)
Abstract ORCID
50.00 9
7 Editorial: Predicting virus evolution: from genome evolution… (10.3389/fviro.2023.1215709)
Abstract ORCID
47.71 8
8 SARS-CoV-2 and the Host Cell: A Tale of Interactions (10.3389/fviro.2021.815388)
ORCID
47.58 79
9 Omicron Spike Protein Has a Positive Electrostatic Surface T… (10.3389/fviro.2022.894531)
ORCID
44.63 60
10 Grand Challenge in Viral Disease Investigation: An Endless E… (10.3389/fviro.2021.692105)
Abstract ORCID
42.25 6
11 Oncogenic Viruses as Entropic Drivers of Cancer Evolution (10.3389/fviro.2021.753366)
ORCID
41.80 46
12 Enterovirus-D68 – a reemerging non-polio enterovirus that ca… (10.3389/fviro.2024.1328457)
ORCID
40.05 39
13 Changes in Symptoms Experienced by SARS-CoV-2-Infected Indiv… (10.3389/fviro.2022.880707)
ORCID
38.91 35
14 Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Sp… (10.3389/fviro.2022.830202)
ORCID
37.63 31
15 Viral-Host Dependency Factors as Therapeutic Targets to Over… (10.3389/fviro.2022.935933)
ORCID
37.28 30
16 Malignancy and viral infections in Sub-Saharan Africa: A rev… (10.3389/fviro.2023.1103737)
ORCID
37.28 30
17 Rapid Diagnostics for Hepatitis B and C Viruses in Low- and… (10.3389/fviro.2021.742722)
ORCID
36.93 29
18 Virus-host protein-protein interactions as molecular drug ta… (10.3389/fviro.2022.959586)
ORCID
36.93 29
19 Investigating the evolutionary origins of the first three SA… (10.3389/fviro.2022.942555)
ORCID
36.18 27
20 A brief view of factors that affect plant virus evolution (10.3389/fviro.2022.994057)
ORCID
35.37 25
21 Frontiers in Virology: An Innovative Platform for Integrativ… (10.3389/fviro.2021.665473)
Abstract ORCID
34.95 4
22 Modeling Human Viral Diseases: Trials and Triumphs (10.3389/fviro.2021.722297)
Abstract ORCID
34.95 4
23 Commentary: MSH3 homology and potential recombination link t… (10.3389/fviro.2022.914888)
Abstract ORCID
34.95 4
24 Investigating the Extent of Primer Dropout in SARS-CoV-2 Gen… (10.3389/fviro.2022.840952)
ORCID
34.51 23
25 Pepper mild mottle virus: a formidable foe of capsicum produ… (10.3389/fviro.2023.1208853)
ORCID
34.51 23
26 Molecular Biology and Diversification of Human Retroviruses (10.3389/fviro.2022.872599)
ORCID
34.04 22
27 The influenza hemagglutinin stem antibody CR9114: Evidence f… (10.3389/fviro.2022.1049134)
ORCID
32.53 19
28 SARS-CoV-2 and the Missing Link of Intermediate Hosts in Vir… (10.3389/fviro.2022.875213)
ORCID
32.53 19
29 Consensus statement from the first RdRp Summit: advancing RN… (10.3389/fviro.2024.1371958)
ORCID
32.53 19
30 Iota-Carrageenan Prevents the Replication of SARS-CoV-2 in a… (10.3389/fviro.2021.746824)
ORCID
31.97 18
31 Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cas… (10.3389/fviro.2022.849936)
ORCID
31.97 18
32 Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vacc… (10.3389/fviro.2022.891540)
ORCID
31.97 18
33 Reliability of Wastewater Analysis for Monitoring COVID-19 I… (10.3389/fviro.2021.776998)
ORCID
31.38 17
34 Effect of Maternal HIV Infection on Infant Development and O… (10.3389/fviro.2022.885246)
ORCID
31.38 17
35 APOBEC3 family proteins as drivers of virus evolution (10.3389/fviro.2023.1332010)
ORCID
31.38 17
36 HIV Modifies the m6A and m5C Epitranscriptomic Landscape of… (10.3389/fviro.2021.714475)
ORCID
30.76 16
37 Phylogenetic-based methods for fine-scale classification of… (10.3389/fviro.2024.1433931)
ORCID
30.76 16
38 Bioinformatics Algorithms and Predictive Models: The Grand C… (10.3389/fviro.2021.684608)
Abstract ORCID
30.10 3
39 Human Anelloviruses: Prevalence and Clinical Significance Du… (10.3389/fviro.2021.782886)
ORCID
30.10 15
40 Downregulation of Transcriptional Activity, Increased Inflam… (10.3389/fviro.2022.782906)
ORCID
30.10 15
41 HIV Co-infection Augments EBV-Induced Tumorigenesis in vivo (10.3389/fviro.2022.861628)
ORCID
30.10 15
42 Corrigendum: MSH3 Homology and Potential Recombination Link… (10.3389/fviro.2022.884169)
Abstract ORCID
30.10 3
43 Virological characteristics correlating with SARS-CoV-2 spik… (10.3389/fviro.2024.1353661)
ORCID
30.10 15
44 Host-Viral Interactions at the Maternal-Fetal Interface. Wha… (10.3389/fviro.2022.833106)
ORCID
29.40 14
45 Serum Proteomics Identifies Immune Pathways and Candidate Bi… (10.3389/fviro.2022.862961)
ORCID
29.40 14
46 Diverse roles of heterogeneous nuclear ribonucleoproteins in… (10.3389/fviro.2022.1044652)
ORCID
28.65 13
47 Antigenic alteration of 2017-2018 season influenza B vaccine… (10.3389/fviro.2022.933440)
ORCID
28.65 13
48 Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibo… (10.3389/fviro.2023.1128253)
ORCID
28.65 13
49 CD4+ T lymphocyte recovery in the modern antiretroviral ther… (10.3389/fviro.2022.822153)
ORCID
27.85 12
50 Identification of Compounds With Antiviral Activity Against… (10.3389/fviro.2022.854363)
ORCID
27.85 12